Medicine

"When it comes to viruses that lead to chronic infection, immune cells receive the wrong set of marching orders, which makes them less responsive."

UFP Technologies, Inc. (Nasdaq:UFPT), a designer and custom converter of foams, plastics and specialty materials, today announced the acquisition of Dielectrics, Inc.  

While some scientists have questioned the existence of chronic Lyme disease, new research confirms that some patients' symptoms last long after they are said to be disease-free.

"It's taken years of trial and error, making educated guesses, and taking baby steps to finally produce functioning human muscle from pluripotent stem cells..."

Antimicrobials have been a driver of unprecedented medical and societal advances, but their overuse has resulted in antibiotic resistant bacteria, with the World Health Organization (WHO) reporting new surveillance data on Monday.

Huntington's may start earlier than we thought—and existing treatments may actually do more harm than good.

Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update

Roche announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its investigational oral medicine balovaptan (previously known as RG7314), a vasopressin 1a (V1a) receptor antagonist for individuals with autism spectrum disorder (ASD).

Researchers have optimized a new method to create synthetic neurons, neuron-like cells created from a readily available cell line.

A mathematical model can replicate cancer cell growth seen in the lab and may help scientists understand more about how tumors form and grow. See the simulation for yourself.

Patients with either HCC or liver metastases frequently cannot undergo surgery and have very few or no therapeutic options available. Radiation therapy has been shown to improve outcomes of these patients.

Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2017 results on Thursday, February 1, 2018, before the market opens

Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features.

"Overall, child mortality in wealthy countries, including the US, is improving, but the progress our country has made is considerably slower than progress elsewhere."

The common blood pressure drug could be a new way to cut stress for melanoma patients receiving immunotherapy and potentially lengthen their lives.